scholarly journals Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection

2021 ◽  
Vol 22 (14) ◽  
pp. 7605
Author(s):  
Weronika Bielka ◽  
Agnieszka Przezak ◽  
Andrzej Pawlik
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Care ◽  
Diabetes Therapy ◽  
Dipeptidyl Peptidase 4 ◽  
Sodium Glucose Cotransporter ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Altered Immune Status ◽  
Glucagon Like Peptide 1 ◽  
Therapeutic Problem

COVID-19 infection poses an important clinical therapeutic problem, especially in patients with coexistent diseases such as type 2 diabetes. Potential pathogenetic links between COVID-19 and diabetes include inflammation, effects on glucose homeostasis, haemoglobin deoxygenation, altered immune status and activation of the renin-angiotensin-aldosterone system (RAAS). Moreover, drugs often used in the clinical care of diabetes (dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, metformin and insulin) may influence the course of SARS-CoV-2 infection, so it is very important to verify their effectiveness and safety. This review summarises the new advances in diabetes therapy and COVID-19 and provides clinical recommendations that are essential for medical doctors and for patients suffering from type 2 diabetes.

scholarly journals Treatment of type 2 diabetes: the stability of the effectiveness of hypoglycemic medications

2016 ◽  
Vol 13 (3) ◽  
pp. 32-36
Author(s):  
Tat'yana Morgunova ◽  
Valentin Fadeev
Keyword(s):  
Type 2 Diabetes ◽  
Meta Analysis ◽  
Original Research ◽  
Dipeptidyl Peptidase 4 ◽  
Sodium Glucose Cotransporter ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
The Stability

This article is dedicated to the problem of glycaemic durability of drugs used in treatment of type 2 diabetes. The results of studies comparing durability of glycemic control as monotherapy or in combination of metformin with different drugs: dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, sulfonylurea, inhibitors of sodium-glucose cotransporter-2 are shown. The article discusses the results of original research and meta-analysis.

scholarly journals Semaglutide (Rybelsus)

2021 ◽  
Vol 1 (6) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Type 2 Diabetes ◽  
Treatment Cost ◽  
Clinical Evidence ◽  
Dipeptidyl Peptidase 4 ◽  
Sodium Glucose Cotransporter ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
High Treatment

Clinical evidence suggests that Rybelsus should be reimbursed to treat type 2 diabetes in adults if it is used in addition to metformin or other antihyperglycemic agents and does not cost more than glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors. Rybelsus is more costly than most similar diabetes treatments. Rybelsus is expected to increase budgets by more than $38 million over 3 years. To account for the high treatment cost, the price of Rybelsus should be reduced. If Rybelsus is not reimbursed as an add-on treatment for patients with type 2 diabetes, there are several other alternative treatments available for these patients.

Adverse Effects Associated With Newer Diabetes Therapies

2016 ◽  
Vol 30 (2) ◽  
pp. 238-244 ◽  
Author(s):  
Oluwaranti F. Akiyode ◽  
Adebola A. Adesoye
Keyword(s):  
Type 2 Diabetes ◽  
Adverse Effects ◽  
Dipeptidyl Peptidase 4 ◽  
Health Care Practitioners ◽  
Sodium Glucose Cotransporter ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Patients With Diabetes ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

The increasing number of newer type 2 diabetes therapies has allowed providers an increased armamentarium for the optimal management of patients with diabetes. In fact, these newer agents have unique benefits in the management of type 2 diabetes. However, they are also associated with certain adverse effects. This review article aims to describe the notable adverse effects of these newer antidiabetic therapies including the glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and the sodium-glucose cotransporter 2 inhibitors. The adverse effects reviewed herein include pancreatitis, medullary thyroid carcinoma, heart failure, gastrointestinal disturbances, renal impairment, and genitourinary infections. More clinical data are necessary to solidify the association of some of these adverse effects with the newer diabetes agents. However, it is important for health care practitioners to be well informed and prepared to properly monitor patients for these adverse effects.

scholarly journals Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

2013 ◽  
pp. 989 ◽  
Author(s):  
Dario Giugliano ◽  
Liberata Sportiello ◽  
Annalisa Capuano ◽  
Mariaida Maiorino ◽  
Francesco Rossi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Diabetes Therapy ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors
Sign in / Sign up

Export Citation Format

Share Document